UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

European journal of heart failure, 2021-02, Vol.23 (2), p.277-285

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years

Amyloid, 2017-07, Vol.24 (3), p.194-204

2017

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

Ophthalmology (Rochester, Minn.), 2011-06, Vol.118 (6), p.1107-1118

2011

Link zum Volltext

Verfügbarkeit prüfen

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Circulation. Heart failure, 2017-06, Vol.10 (6)

2017

Link zum Volltext

Verfügbarkeit prüfen

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Investigative ophthalmology & visual science, 2018-05, Vol.59 (6), p.2659-2669

2018

Link zum Volltext

Verfügbarkeit prüfen

Understanding the Importance of IOP Variables in Glaucoma: A Systematic Review

Survey of ophthalmology, 2009-11, Vol.54 (6), p.643-662

2009

Link zum Volltext

Verfügbarkeit prüfen

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Clinical Medicine Insights. Cardiology, 2017, Vol.2017 (11), p.1179546817730322-1179546817730322

2017

Link zum Volltext

Verfügbarkeit prüfen

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

ESC Heart Failure, 2021-10, Vol.8 (5), p.3875-3884

2021

Link zum Volltext

Verfügbarkeit prüfen

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

The New England journal of medicine, 2018-09, Vol.379 (11), p.1007-1016

2018

Link zum Volltext

Verfügbarkeit prüfen

Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”

Circulation. Heart failure, 2022-07, Vol.15 (7), p.e009637-e009637

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’

European journal of heart failure, 2021-06, Vol.23 (6), p.1057-1058

2021

Link zum Volltext

Verfügbarkeit prüfen

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Neurology and therapy, 2018-06, Vol.7 (1), p.87-101

2018

Link zum Volltext

Verfügbarkeit prüfen

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

European journal of heart failure, 2023-11, Vol.25 (11), p.2060-2064

2023

Link zum Volltext

Verfügbarkeit prüfen

Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death

Cardiology, 2022-10, Vol.147 (4), p.398-405

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation. Heart failure, 2022-01, Vol.15 (1), p.e008193-e008193

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

The American journal of cardiology, 2021-02, Vol.141, p.98-105

2021

Link zum Volltext

Verfügbarkeit prüfen

Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])

The American journal of cardiology, 2021-06, Vol.148, p.146-150

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy

European journal of heart failure, 2024-03, Vol.26 (3), p.612-615

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT

JACC. Heart failure, 2021-02, Vol.9 (2), p.115-123

2021

Link zum Volltext

Verfügbarkeit prüfen

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study

JACC. Heart failure, 2024-01, Vol.12 (1), p.150-160

2024

Link zum Volltext

Verfügbarkeit prüfen

A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Amyloid, 2022-10, Vol.29 (4), p.228-236

2022

Link zum Volltext

Verfügbarkeit prüfen

A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus

BMC ophthalmology, 2012-08, Vol.12 (1), p.37-37, Article 37

2012

Link zum Volltext

Verfügbarkeit prüfen

Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy

JACC. Heart failure, 2021-05, Vol.9 (5), p.404-404

2021

Link zum Volltext

Verfügbarkeit prüfen

A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy

Amyloid, 2019-10, Vol.26 (4), p.203-209

2019

Link zum Volltext

Verfügbarkeit prüfen

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers

Clinical pharmacology in drug development, 2020-10, Vol.9 (7), p.849-854

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(58)
Buchkapitel
(2)

Sprache

Englisch
(60)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(38)
Science & Technology
(38)
Humans
(25)
Cardiac & Cardiovascular Systems
(19)
Cardiovascular System & Cardiology
(19)
Amyloidosis
(14)
Ophthalmology
(13)
Transthyretin
(13)
Heart Failure
(12)
Cardiomyopathy
(11)
Amyloid Neuropathies, Familial - Drug Therapy
(10)
Female
(10)
Male
(10)
Tafamidis
(10)
Cardiomyopathies - Drug Therapy
(9)
Aged
(8)
Middle Aged
(8)
Aged, 80 And Over
(7)
Benzoxazoles - Therapeutic Use
(7)
Clinical Trials
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years

A Phase 2/3, Multicenter, Randomized, Double-Masked, 2-Year Trial of Pegaptanib Sodium for the Treatment of Diabetic Macular Edema

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Understanding the Importance of IOP Variables in Glaucoma: A Systematic Review

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])

Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study

A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)

A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus

Reply: Bio-Profiling of Transthyretin Amyloid Cardiomyopathy

A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers

Suchergebnisse filtern